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L E T T E R
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Dear editor
We read with interest the article by Tamaki et al who in the OCEAN study 
compared the performance characteristics of the CAPTURE COPD screening tool 
with the COPD-Q screening tool.1 While there is currently an important focus on 
better understanding the broader scope of symptomatic chronic lung disease, it is 
useful to remember that the CAPTURE was designed specifically to be used as 
a screening tool (meaning to be used among those without a COPD diagnosis) for 
the identification of individuals with clinically significant COPD.
We designed the CAPTURE tool to specifically identify individuals who would 
benefit from immediate pharmacologic therapy, beyond the preventive strategies 
that should already be important for everyone in a primary care practice—smoking 
cessation, up to date immunizations, weight management and regular activity. We 
defined clinically significant COPD as chronic lung disease meeting the obstructive 
lung disease lung function definition (FEV1/FVC < 0.70) in addition to either FEV1 
<60% of predicted or evidence of exacerbation like events in the prior year.2 These 
are individuals for whom data have shown immediate benefit with pharmacotherapy 
in improving quality of life and preventing future exacerbations.3 In addition, when 
CAPTURE was previously validated in a combined primary care and specialty 
patient study using the 5 questions that OCEAN used with the addition of peak flow 
assessment, it was found to significantly improve screening outcomes, particularly 
supporting specificity which has been a concern with many prior screening tools.2
The OCEAN study is a valuable reminder that we may need to develop tools for 
screening for PRISm (Preserved Ratio Impaired Spirometry).4 We will learn more 
about the utility of CAPTURE to detect clinically significant COPD through a large 
primary care validation and impact study currently being conducted in the US.5
Acknowledgments
The CAPTURE Investigators: Meldrum C, Murray S, Spino C, Leidy N, Tapp H, 
Dolor R, Joo M, Knox L, Zittleman L, Elder N, Thomashow BM.
Disclosure
Dr Barry Make reports grants, personal fees from Astra Zeneca, personal fees 
from Spiration, grants, personal fees from Glaxo Smith Kline, personal fees 
from Mt. Sinai, personal fees from Web MD, personal fees from National 
Jewish Health, personal fees from Novartis, personal fees from American 
Correspondence: Barbara P Yawn  
Email byawn47@gmail.com
International Journal of Chronic Obstructive Pulmonary Disease 2021:16 2501–2502               2501
© 2021 Yawn et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work 
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
International Journal of Chronic Obstructive Pulmonary Disease           Dovepress
open access to scientific and medical research
Open Access Full Text Article
Received: 4 August 2021
Accepted: 23 August 2021

















































































Powered by TCPDF (www.tcpdf.org)
College of Chest Physicians, personal fees from 
Projects in Knowledge, personal fees from Medscape, 
personal fees from Verona, personal fees from 
Boehringer Ingelheim, personal fees from Mylan, per-
sonal fees from Third Pole, personal fees from Phillips, 
personal fees from Eastern Pulmonary Society, grants 
from NHLBI, personal fees from Wolters Kluwer 
Health, personal fees from Optimum Patient Care 
Global Limited, personal fees from Integritas 
Communications, personal fees from Quintiles, outside 
the submitted work. Dr David Mannino reports perso-
nal fees from GlaxoSmithKline, outside the submitted 
work. Dr Fernando Martinez reports grants, personal 
fees, non-financial support from AstraZeneca, personal 
fees from Boehringer Ingelheim, grants, COPD Study 
Steering committee from Chiesi, personal fees from 
CsL Behring, non-financial support, COPD Ad Board 
from Gala, grants, non-financial support, COPD Ad 
Boards, Study Steering Committee, Non-branded pre-
sentations; AZ is an independent sponsor of the 
NHLBI CAPTURE validation study from 
GlaxoSmithKline, COPD Study adjudication committee 
from Medtronic, personal fees from Novartis, personal 
fees from Polarean, COPD Advisory Board from 
Pulmonx, grants, personal fees from Sanofi/ 
Regeneron, personal fees from Sunovion, personal 
fees from Teva, personal fees from Theravance/ 
Viatris, COPD Advisory Board from Verona, during 
the conduct of the study. Dr Meilan K Han reports 
personal fees from AZ, personal fees from BI, personal 
fees from Chiesi, personal fees from Cipla, personal 
fees from GSK, personal fees from Merck, drug supply 
for clinical trial and clinical trial with funds paid to 
institution from Novartis, grants from Sunovion, perso-
nal fees, consulting and clinical trial with funds paid to 
institution from Sanofi, personal fees from Teva, per-
sonal fees from Verona, outside the submitted work. 
The authors report no other conflicts of interest in this 
communication.
References
1. Tamaki K, Sakihara E, Miyata H, et al. Utility of self-administered 
questionnaires for identifying individuals at risk of COPD in Japan: 
the OCEAN (Okinawa COPD casE finding AssessmeNt) Study. 
Int J Chron Obstruct Pulmon Dis. 2021;16:1771–1782. doi:10.2147/ 
COPD.S302259
2. Martinez FJ, Mannino D, Leidy NK, et al. A new approach for 
identifying patients with undiagnosed chronic obstructive pulmonary 
disease. Am J Respir Crit Care Med. 2017;195(6):748–756. 
doi:10.1164/rccm.201603-0622OC
3. Decramer M, Miravitlles M, Price D, et al. New horizons in early stage 
COPD–improving knowledge, detection and treatment. Respir Med. 
2011;105(11):1576–1587. doi:10.1016/j.rmed.2010.12.015
4. Wan ES, Fortis S, Regan EA, et al; COPDGene Investigators. 
Longitudinal phenotypes and mortality in preserved ratio impaired 
spirometry in the COPDGene Study. Am J Respir Crit Care Med. 
2018;198(11):1397–1405. doi:10.1164/rccm.201804-0663OC
5. Yawn BP, Han M, Make BM, et al. Protocol summary of the 
COPD assessment in primary care to identify undiagnosed respira-
tory disease and exacerbation risk (CAPTURE) validation in 
Primary Care Study. Chronic Obstr Pulm Dis. 2021;8(1):60–75.
Dove Medical Press encourages responsible, free and frank academic debate. The content of the International Journal of Chronic Obstructive Pulmonary Disease ‘letters to the editor’ 
section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the International Journal of Chronic Obstructive Pulmonary 
Disease editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it 
responsible for the content and accuracy of any letter to the editor.  
International Journal of Chronic Obstructive Pulmonary Disease                                                       Dovepress 
Publish your work in this journal 
The International Journal of COPD is an international, peer-reviewed 
journal of therapeutics and pharmacology focusing on concise rapid 
reporting of clinical studies and reviews in COPD. Special focus is 
given to the pathophysiological processes underlying the disease, inter-
vention programs, patient focused education, and self management 
protocols. This journal is indexed on PubMed Central, MedLine 
and CAS. The manuscript management system is completely online 
and includes a very quick and fair peer-review system, which is 
all easy to use. Visit http://www.dovepress.com/testimonials.php to 
read real quotes from published authors.  
Submit your manuscript here: https://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal
DovePress                                                           International Journal of Chronic Obstructive Pulmonary Disease 2021:16 2502
https://doi.org/10.2147/COPD.S332598
Yawn et al                                                                                                                                                             Dovepress
Powered by TCPDF (www.tcpdf.org)
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic
 O
bs
tr
uc
tiv
e 
P
ul
m
on
ar
y 
D
is
ea
se
 d
ow
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
17
4.
20
2.
39
.9
0 
on
 0
6-
S
ep
-2
02
1
F
or
 p
er
so
na
l u
se
 o
nl
y.
